This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Prior treatment

• Have received prescription medication or non-prescription medication for weight loss within the last 3 months prior to screening.
• Treatment with diabetes medication in past 3 months prior to screening.
• Prior history of cholecystectomy or untreated cholelithiasis.
• History of marijuana or THC use within 3 months before screening, or unwilling/unable to abstain from marijuana or THC use during the study.
• Previous hospitalisation for any psychiatric reason.
• PHQ-9 score ≥ 15 within the 2 years prior to screening or at screening.

Other illness

• Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract.
• Severely uncontrolled hypertension defined as systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg on the average of 2 seated measurements after being at rest for at least 5 minutes.
• History of psychosis or bipolar disorder.

Lab values

• History of type 1 or type 2 diabetes mellitus or symptoms indicative of insulinopenia or poor glucose control.
• HbA1c ≥ 6.5% (48 mmol/mol) at screening.
• Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:
  • AST ≥ 2.5 × ULN
  • ALT ≥ 2.5 × ULN
  • TBL ≥ 1.5 × ULN.
• History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening.
• Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73 m2 at screening (GFR estimated according to CKD-EPI).
• Uncontrolled thyroid disease, defined as TSH \> ULN or \< LLN for the laboratory reference range, as judged by the PI at screening.
  • Sub-study 2 only

Other

• Gastroparesis (or similar) requiring treatment.
• HR \< 50 bpm or \> 100 bpm after being at rest for 5 minutes.
• Severe vitamin D deficiency defined as a 25-OH vitamin D level \< 12 ng/mL.
• Personal or family history (first-degree relative) of MTC or MEN2.

• Age 18 to 55 years.
• BMI ≥ 27 kg/m2.
• Stable body weight for 3 months prior to screening.
• Male and female (Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies).
• Participants should refrain from blodd donation throughout the sub-study, including the follow-up period.
• Negative pregnancy test at screening and randomisation for FOCBP and must not be breastfeeding.